American Oriental Bioengineering, Inc. (AOBI)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2012 | 446.3 Million USD | -21.0% |
| 2011 | 564.98 Million USD | -7.61% |
| 2010 | 611.54 Million USD | 6.08% |
| 2009 | 576.48 Million USD | 10.0% |
| 2008 | 524.05 Million USD | 48.16% |
| 2007 | 353.71 Million USD | 90.91% |
| 2006 | 185.27 Million USD | 86.35% |
| 2005 | 99.42 Million USD | 132.1% |
| 2004 | 42.83 Million USD | 97.65% |
| 2003 | 21.67 Million USD | 99.78% |
| 2002 | 10.84 Million USD | 2642.39% |
| 2001 | 395.56 Thousand USD | 531.61% |
| 2000 | 62.62 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2013 Q1 | 423.72 Million USD | -5.06% |
| 2013 Q3 | 427.62 Million USD | 2.11% |
| 2013 Q2 | 418.8 Million USD | -1.16% |
| 2012 Q1 | 549.86 Million USD | -2.68% |
| 2012 FY | 446.3 Million USD | -21.0% |
| 2012 Q4 | 446.3 Million USD | -10.95% |
| 2012 Q3 | 501.16 Million USD | -5.52% |
| 2012 Q2 | 530.45 Million USD | -3.53% |
| 2011 FY | 564.98 Million USD | -7.61% |
| 2011 Q4 | 564.98 Million USD | -11.58% |
| 2011 Q3 | 639 Million USD | 1.3% |
| 2011 Q2 | 630.82 Million USD | 2.64% |
| 2011 Q1 | 614.61 Million USD | 0.5% |
| 2010 Q2 | 586.39 Million USD | 1.68% |
| 2010 Q1 | 576.71 Million USD | 0.04% |
| 2010 Q3 | 604.13 Million USD | 3.03% |
| 2010 FY | 611.54 Million USD | 6.08% |
| 2010 Q4 | 611.54 Million USD | 1.23% |
| 2009 FY | 576.48 Million USD | 10.0% |
| 2009 Q1 | 524.86 Million USD | 0.15% |
| 2009 Q2 | 540.79 Million USD | 3.04% |
| 2009 Q3 | 562.33 Million USD | 3.98% |
| 2009 Q4 | 576.48 Million USD | 2.52% |
| 2008 Q1 | 370.7 Million USD | 4.8% |
| 2008 FY | 524.05 Million USD | 48.16% |
| 2008 Q4 | 524.05 Million USD | 4.0% |
| 2008 Q3 | 503.9 Million USD | 27.07% |
| 2008 Q2 | 396.55 Million USD | 6.97% |
| 2007 Q1 | 192.36 Million USD | 3.83% |
| 2007 Q2 | 207.58 Million USD | 7.91% |
| 2007 Q3 | 317.45 Million USD | 52.93% |
| 2007 Q4 | 353.71 Million USD | 11.42% |
| 2007 FY | 353.71 Million USD | 90.91% |
| 2006 Q3 | 167.22 Million USD | 6.78% |
| 2006 FY | 185.27 Million USD | 86.35% |
| 2006 Q1 | 130.53 Million USD | 31.3% |
| 2006 Q2 | 156.6 Million USD | 19.97% |
| 2006 Q4 | 185.27 Million USD | 10.79% |
| 2005 Q4 | 99.42 Million USD | 58.86% |
| 2005 Q3 | 62.58 Million USD | 23.19% |
| 2005 Q2 | 50.8 Million USD | 11.41% |
| 2005 Q1 | 45.59 Million USD | 6.45% |
| 2005 FY | 99.42 Million USD | 132.1% |
| 2004 Q3 | 28.61 Million USD | 14.39% |
| 2004 Q4 | 42.83 Million USD | 49.72% |
| 2004 FY | 42.83 Million USD | 97.65% |
| 2004 Q1 | 24.8 Million USD | 14.46% |
| 2004 Q2 | 25.01 Million USD | 0.83% |
| 2003 Q2 | 17.58 Million USD | 9.76% |
| 2003 Q1 | 16.02 Million USD | 47.68% |
| 2003 FY | 21.67 Million USD | 99.78% |
| 2003 Q4 | 21.67 Million USD | 4.56% |
| 2003 Q3 | 20.72 Million USD | 17.87% |
| 2002 Q4 | 10.84 Million USD | 0.13% |
| 2002 Q1 | 395.56 Thousand USD | 0.0% |
| 2002 Q2 | 10.32 Million USD | 2509.89% |
| 2002 Q3 | 10.83 Million USD | 4.94% |
| 2002 FY | 10.84 Million USD | 2642.39% |
| 2001 Q2 | 76.00 USD | -99.85% |
| 2001 Q3 | 76.00 USD | 0.0% |
| 2001 Q4 | 395.56 Thousand USD | 520382.89% |
| 2001 FY | 395.56 Thousand USD | 531.61% |
| 2001 Q1 | 50 Thousand USD | -20.16% |
| 2000 Q2 | 59.77 Thousand USD | 0.19% |
| 2000 Q1 | 59.65 Thousand USD | 0.0% |
| 2000 Q4 | 62.62 Thousand USD | -45.11% |
| 2000 FY | 62.62 Thousand USD | 0.0% |
| 2000 Q3 | 114.09 Thousand USD | 90.88% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -19320632.641% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -22691.923% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -4128.813% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -80735.493% |
| Rebus Holdings, Inc. | 5000.00 USD | -8926078.48% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -242.759% |
| Qrons Inc. | 420.00 USD | -106263929.524% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -57813.761% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -1497.155% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -92773.254% |
| Skye Bioscience, Inc. | 11.94 Million USD | -3637.802% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -1048.889% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -6081.768% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -584425.924% |
| SQZ Biotechnologies Company | 107.18 Million USD | -316.383% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -31066.128% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -616646.941% |
| Mesoblast Limited | 667.9 Million USD | 33.177% |
| Marizyme, Inc. | 22.01 Million USD | -1927.288% |
| Genus plc | 1.02 Billion USD | 56.623% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -32756.623% |
| Pharming Group N.V. | 462.85 Million USD | 3.575% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -13371.395% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -89333.676% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -71081.647% |
| ContraFect Corporation | 20.67 Million USD | -2058.271% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -114230.89% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -116680.686% |
| IMV Inc. | 31.33 Million USD | -1324.37% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -10664.751% |
| MultiCell Technologies, Inc. | 126.22 USD | -353595941.832% |
| ONE Bio Corp. | 70.08 Million USD | -536.806% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -47395.387% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -247.295% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -103280.693% |
| Q BioMed Inc. | 3.51 Million USD | -12595.399% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -1168.68% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -170718.298% |
| Biomind Labs Inc. | 73.81 Thousand USD | -604498.984% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -30704.506% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -1386.955% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -16151.074% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -64818.984% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -17044.653% |
| GB Sciences, Inc. | 103.44 Thousand USD | -431358.135% |
| Alpha Cognition Inc. | 2.45 Million USD | -18100.57% |
| HST Global, Inc. | 1526.00 USD | -29246880.603% |
| CSL Limited | 38.02 Billion USD | 98.826% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -45074.477% |
| Halberd Corporation | 10.13 Thousand USD | -4405278.778% |
| Enzolytics Inc. | 361.7 Million USD | -23.39% |
| Agentix Corp. | 261.39 Thousand USD | -170643.146% |
| Resverlogix Corp. | 8.11 Million USD | -5399.802% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -23666.637% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 90.175% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -835.619% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -69673.273% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1959027.887% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -4887.163% |
| AVAX Technologies, Inc. | 7.37 Million USD | -5949.877% |
| Zenith Capital Corp. | 7410.00 USD | -6022962.402% |
| Genscript Biotech Corporation | 3.38 Billion USD | 86.82% |
| Ember Therapeutics, Inc. | 184.00 USD | -242559097.826% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -138588.814% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -170661.438% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -47995.655% |
| Kadimastem Ltd | 2.3 Million USD | -19270.374% |
| Helix BioMedix, Inc. | 3.02 Million USD | -14653.595% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -746.87% |
| BioStem Technologies, Inc. | 14.56 Million USD | -2965.247% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -781608.978% |
| LadRx Corporation | 2.3 Million USD | -19238.464% |
| Cell Source, Inc. | 195.17 Thousand USD | -228575.84% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -126112.519% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -126112.519% |
| NovAccess Global Inc. | 62.24 Thousand USD | -716885.163% |
| Affymax, Inc. | 7.44 Million USD | -5896.358% |
| Itoco Inc. | 1.4 Million USD | -31777.569% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -466472.153% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -420946.155% |
| Mobile Lads Corp. | 52.00 USD | -858286292.308% |
| CytoDyn Inc. | 11.13 Million USD | -3907.803% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -312065.266% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2496034.922% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -115682.75% |
| SYBLEU INC | 330.46 Thousand USD | -134953.598% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -108909.512% |
| International Stem Cell Corporation | 5.39 Million USD | -8180.314% |
| Bioxytran, Inc. | 137.63 Thousand USD | -324162.866% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -2875.03% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -2592.014% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -564848.005% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -51515.681% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -5837.328% |
| Neutra Corp. | 2851.00 USD | -15654369.449% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1277.242% |
| PureTech Health plc | 693.97 Million USD | 35.688% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -5429.724% |
| IXICO plc | 15.84 Million USD | -2716.913% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -5288.903% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -331.951% |
| CSL Limited | 38.02 Billion USD | 98.826% |
| Cellectis S.A. | 333.99 Million USD | -33.628% |